Study on Eltrombopag for Treating Low and Intermediate Risk Myelodysplastic Syndromes in Patients with Thrombocytopenia
- Substances:Eltrombopag
Italy- Participants:18–64 years · 65+ years
- Substances:Eltrombopag
- Sponsor:Associazione Qol-One
Rare diseases
Investigational molecules
Locations

Via Carro E Quattrone 8, 89134 Reggio Calabria, Italy
Associazione Qol-One funds clinical research in myelodysplastic syndromes, with a specific focus on del(5q) disease and lower-risk forms defined by IPSS-R categories. The sponsored trials address patients with limited prior treatment options and ongoing bone marrow failure.
The research landscape includes patients with very low, low, and intermediate risk disease, reflecting a therapeutic interest in clinically significant but less advanced myelodysplastic conditions.
Associazione Qol-One runs clinical trials in conditions such as Myelodysplastic syndrome, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Italy
ItalyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.